← Eichor
Condition: Glp1 Agonist Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Glp1 Agonist

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Restoring Facial Volume After GLP-1 Weight Loss With Radiesse
Phase 4 · 1 location(s) · Kalpna Kay Durairaj, MD, FACS · NCT07419854Efficacy of a GLP-1/FGF21 Dual Agonist for Treating PCOS
Phase 2 · 1 location(s) · Shanghai Zhongshan Hospital · NCT07616037Tirzepatide to Slow Biological Aging
Phase 2 · 1 location(s) · The University of Texas Medical Branch, Galveston · NCT07220473Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.
Phase 4 · 5 location(s) · Fundacion Dexeus · NCT07242534Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabol
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT07202247GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
Phase 3 · 8 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT07083154Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity
Phase 4 · 1 location(s) · Nordsjaellands Hospital · NCT07136714iGlarLixi CGM Study in Chinese T2D Individuals After OADs
Phase 4 · 1 location(s) · Sanofi · NCT06671587GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
Phase 2 · 2 location(s) · University of Pennsylvania · NCT04731272Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
Phase 2 · 1 location(s) · Hudson Biotech · NCT07467447A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel I
Phase 2 · 1 location(s) · University of Florida · NCT07107334A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar
Phase 2/Phase 3 · 4 location(s) · McGill University Health Centre/Research Institute of the Mc · NCT07284511Creatine Supplementation During GLP-1a Therapy
NA · 1 location(s) · University of Saskatchewan · NCT07625202Body Surface Gastric Mapping in Patients on Semaglutide
Phase N/A · 1 location(s) · University of Western Sydney · NCT06401746Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)
NA · 1 location(s) · National Health Research Institutes, Taiwan · NCT06271200GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery
Phase 4 · 3 location(s) · The University of Hong Kong · NCT06324461Effect of GLP-1 Receptor Agonists on Body Composition in Obesity: The Role of Dietary Protein Consumption in Muscle Mass
NA · 2 location(s) · Hellenic Mediterranean University · NCT07495904The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality
Phase 4 · 3 location(s) · The Cleveland Clinic · NCT07127354Magnetic Resonance Imaging Assessment of Multiorgan Health in Obesity
Phase N/A · 1 location(s) · Alder Hey Children's NHS Foundation Trust · NCT07702825Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy
NA · 1 location(s) · Kazakh Academy of Nutrition · NCT07728669Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.
Phase N/A · 1 location(s) · National and Kapodistrian University of Athens · NCT07653412A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), a
Phase 2 · 7 location(s) · Actimed Therapeutics Ltd · NCT07101939Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Recept
NA · 1 location(s) · The University of Texas Health Science Center, Houston · NCT06654219Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GL
Phase 2 · 14 location(s) · Veru Inc. · NCT07446998Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polyc
Phase N/A · 1 location(s) · Nemours Children's Clinic · NCT07169136Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
Phase 4 · 1 location(s) · University of Miami · NCT06774079Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness
NA · 1 location(s) · University Hospital Tuebingen · NCT06487832JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide i
Phase 4 · 1 location(s) · McMaster University · NCT06852391Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery
NA · 1 location(s) · Centre Hospitalier Universitaire de Nice · NCT06278285Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
Phase 2 · 4 location(s) · University of Washington · NCT05822609
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.